Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for ZLDPF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 63.85M
March 31, 2026 -105.24M
December 31, 2025 -168.06M
September 30, 2025 -32.01M
June 30, 2025 1.289B
March 31, 2025 -70.65M
December 31, 2024 -22.63M
September 30, 2024 -43.49M
June 30, 2024 -33.38M
March 31, 2024 -32.56M
December 31, 2023 8.582M
September 30, 2023 -16.45M
June 30, 2023 -25.68M
March 31, 2023 -28.35M
December 31, 2022 -37.34M
September 30, 2022 -17.05M
June 30, 2022 -30.12M
March 31, 2022 -47.80M
December 31, 2021 -42.92M
September 30, 2021 -30.64M
June 30, 2021 -53.08M
March 31, 2021 -59.62M
December 31, 2020 -44.38M
September 30, 2020 -15.40M
June 30, 2020 -14.93M
Date Value
March 31, 2020 -31.32M
December 31, 2019 -24.80M
September 30, 2019 -22.43M
June 30, 2019 -21.00M
March 31, 2019 7.438M
December 31, 2018 -22.77M
September 30, 2018 -15.58M
June 30, 2018 -17.69M
March 31, 2018 -15.32M
December 31, 2017 -16.83M
September 30, 2017 -1.372M
June 30, 2017 -18.46M
March 31, 2017 -7.435M
December 31, 2016 16.86M
September 30, 2016 -6.872M
June 30, 2016 -9.381M
March 31, 2016 6.101M
December 31, 2015 -6.694M
September 30, 2015 -9.080M
June 30, 2015 -8.563M
March 31, 2015 -9.214M
December 31, 2014 -6.152M
September 30, 2014 0.941M
June 30, 2014 -9.487M
March 31, 2014 7.492M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Genmab A/S 51.04M
Ascendis Pharma A/S 327.52M
Bavarian Nordic A/S 55.02M
Evaxion AS --
ACADIA Pharmaceuticals, Inc. 100.78M